The simultaneous administration of the PARP inhibitor olaparib with the ATR inhibitor ceralasertib, for instance, has been correlated with the onset of anemia, neutropenia, and thrombocytopenia54,55. The gene discussed is PARP1; the disease is anemia (phenotype).